Literature DB >> 12844465

Management of diabetic and hypertensive cardiovascular disease.

Edward D Frohlich1, James R Sowers.   

Abstract

The simultaneous occurrence of essential hypertension and diabetes mellitus is exceedingly common. In recent years the treatment of the cardiovascular and renal complications has not only become more specific but more effective. The evidence-based medicine data have been provided through many large multicenter studies and strongly support the promise not only of effective treatment in retarding the progression of target-organ involvement, but also the potential of reversal. These dramatic therapeutic improvements have been made possible by wedding the involved pathophysiologic disease mechanisms with the actions of pharmacologic agents. Inherent in this concept is the promise of retarding the development of the cardiovascular and renal morbid events and also reducing their associated mortal endpoints.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12844465     DOI: 10.1007/s11906-003-0039-4

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  45 in total

1.  Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

Authors: 
Journal:  Circulation       Date:  2002-12-17       Impact factor: 29.690

Review 2.  The heart in hypertension.

Authors:  E D Frohlich; C Apstein; A V Chobanian; R B Devereux; H P Dustan; V Dzau; F Fauad-Tarazi; M J Horan; M Marcus; B Massie
Journal:  N Engl J Med       Date:  1992-10-01       Impact factor: 91.245

3.  Apoptosis and glomerular injury after prolonged nitric oxide synthase inhibition in spontaneously hypertensive rats.

Authors:  H Ono; Y Ono; A Takanohashi; H Matsuoka; E D Frohlich
Journal:  Hypertension       Date:  2001-12-01       Impact factor: 10.190

Review 4.  Vascular and cardiac benefits of angiotensin receptor blockers.

Authors:  Ernesto L Schiffrin
Journal:  Am J Med       Date:  2002-10-01       Impact factor: 4.965

Review 5.  Diabetes, hypertension, and cardiovascular disease: an update.

Authors:  J R Sowers; M Epstein; E D Frohlich
Journal:  Hypertension       Date:  2001-04       Impact factor: 10.190

6.  The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.

Authors:  H H Parving; H Lehnert; J Bröchner-Mortensen; R Gomis; S Andersen; P Arner
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

7.  Effects on blood lipids of a blood pressure-lowering diet: the Dietary Approaches to Stop Hypertension (DASH) Trial.

Authors:  E Obarzanek; F M Sacks; W M Vollmer; G A Bray; E R Miller; P H Lin; N M Karanja; M M Most-Windhauser; T J Moore; J F Swain; C W Bales; M A Proschan
Journal:  Am J Clin Nutr       Date:  2001-07       Impact factor: 7.045

8.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.

Authors: 
Journal:  Lancet       Date:  2000-01-22       Impact factor: 79.321

9.  Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Lars H Lindholm; Hans Ibsen; Björn Dahlöf; Richard B Devereux; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Stevo Julius; Sverre E Kjeldsen; Krister Kristiansson; Ole Lederballe-Pedersen; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel; Peter Aurup; Jonathan Edelman; Steven Snapinn
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

10.  Hemodynamic factors in the pathogenesis and maintenance of hypertension.

Authors:  E D Frohlich
Journal:  Fed Proc       Date:  1982-06
View more
  1 in total

1.  Recent publications by ochsner authors.

Authors: 
Journal:  Ochsner J       Date:  2003
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.